ASH17 Archives -

The American Society for Hematology congress was dominated by CAR-T therapies – their potential new uses, how to

CAR-Ts dominated the agenda at ASH 2017

https://pharmaphorum.com/views-analysis-oncology/car-ts-dominated-agenda-ash-2017/

A leukaemia combination therapy could help revive the fortunes of Roche and AbbVie, following late-stage trial results showing

Roche/AbbVie combination could raise standards in CLL

https://pharmaphorum.com/news/rocheabbvie-combination-better-chemo-cll/

Gilead hopes CDL technology will create therapies targeting solid tumours

Gilead goes full throttle on CAR-Ts with $567m acquisition

https://pharmaphorum.com/news/gilead-buy-cell-design-labs-567-million/

While clinicians attending the American Society of Hematology meeting in Atlanta this weekend were anticipating a flurry of

‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shine

https://pharmaphorum.com/news/cure-hemophilia-within-reach-biomarin-spark-gene-therapies-shine/

Gene therapy company Spark Therapeutics has published data showing its one-time treatment can almost entirely eliminate bleeds in

Spark and Pfizer’s gene therapy wows in haemophilia B

https://pharmaphorum.com/news/spark-pfizers-gene-therapy-wows-haemophilia-b/

As the American Society of Hematology’s 2017 congress approaches, there’s plenty to be excited about – not just

ASH 2017: CAR-T therapy and beyond

https://pharmaphorum.com/views-analysis-oncology/ash-2017-car-t-therapy-beyond/

ASH17